Ultramicronized palmitoylethanolamide (Um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): Retrospective observational study on 407 patients
(2019)
fibromyalgia syndrome is a chronic multifaceted disease characterized by widespread pain, muscle stiffness, fatigue, unrefreshing sleep and cognitive disorders. To date, no medication has been shown to significantly improve pain, associated symptoms and Quality of Life in fibromyalgic patients.
Id prodotto:
109340
Handle IRIS:
11562/997490
ultima modifica:
17 febbraio 2024
Citazione bibliografica:
Schweiger, V; Martini, A; Bellamoli, Paola; Donadello, K; Schievano, C; Del Balzo, G; Sarzi-Puttini, P; Parolini, M; Polati, E,
Ultramicronized palmitoylethanolamide (Um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): Retrospective observational study on 407 patients«CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS»
, vol. 18
, n. 4
, 2019
, pp. 326-333